ALK and neuroblastoma: This model offers an ideal platform for the development of therapies that target expression of crizotinib-resistant ALK-positive neuroblastoma, such as combined ALK and mTOR inhibitors, or ALK and ERK5 inhibition (Berry et al., 2012; Umapathy et al., 2014).